Longtermgevity

Pioneering the treatment of nerve damage with topical psychedelics


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

ADDRESSING CHRONIC PAIN WITH NEUROMEDICINE
LongTermGevity Overview


LongTermGevity is pioneering the use of stabilized psilocin to treat the world’s leading cause of disability via non-invasive targeted neuron repair.

Our proprietary transdermal gel, coupled with electrical stimulation, will treat nerve damage in patients with spinal cord and back injuries. 

ADDRESSING CHRONIC PAIN WITH NEUROMEDICINE
The No. 1 Contributor to Disability

1.7 billion people around the world suffer from musculoskeletal disorders (MSDs), making them the leading contributor to disability.1

$14 billion is spent every year on nerve damage therapy, yet traditional therapies are highly invasive, painful or ineffective in the long term.

  • Surgical implants are invasive and can only mask pain.
  • Electrical nerve stimulation may provide relief but does not repair.
  • Opioids are a current standard of pain treatment with highly addictive properties and known dangerous side effects

ADDRESSING CHRONIC PAIN WITH NEUROMEDICINE
Topical Psychedelic Treatment 

LongTermGevity’s novel formulation and patented delivery system of psilocin gel and electrical stimulation treat nerve damage on the spinal cord and back.

ADDRESSING CHRONIC PAIN WITH NEUROMEDICINE
How It Works

Our method involves the use of our LTG Q112 psilocin Electrogel to stimulate neuron receptors the same way they are stimulated in the brain to repair the spinal cord.

Psilocin has been proven to affect the same receptors in the brain that we are targeting in the spinal cord.

Our patented method of stabilization will allow us to apply psilocin on the skin in conjunction with a proven method of electrical stimulation to break the spinal cord blood barrier and reach damaged nerves.

ADDRESSING CHRONIC PAIN WITH NEUROMEDICINE
Early Traction & Accomplishments 

LongTermGevity holds 3 U.S. provisional patents:

  • U.S. Provisional Pat. App. No. 63/305,259
  • U.S. Provisional Pat. App. No. 63/276,005
  • U.S. Provisional Pat. App. No. 63/276,000

We have several partnerships including:

  • Spaulding Clinic
  • GSD Labs
  • Dr.Gerome Manson of Queens University 

Commencing pre-clinical, animal and clinical trials in 2022:

  • Approval from Health Canada to conduct research, product development and commercial activities expected March 2022.
  • Obtained ethics permission from Queen’s University to start Phase I clinical trials.
  • Data to be submitted to FDA for fast-track designation to expedite development.

ADDRESSING CHRONIC PAIN WITH NEUROMEDICINE
Meet The Team 

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.